Allopurinol is the most frequent cause of Stevens-Johnson syndrome and toxic epidermal necrolysis

Expert Review of Dermatology

Volumn 7, Issue 3, 2012, Pages 213-215

  Mockenhaupt, Maja ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

allopurinol; severe cutaneous adverse reactions; Stevens Johnson syndrome; toxic epidermal necrolysis

Indexed keywords

ALLOPURINOL; CARBAMAZEPINE; COTRIMOXAZOLE; HLA B ANTIGEN; LAMOTRIGINE; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN;

AGE; ALLELE; CLINICAL FEATURE; DISEASE SEVERITY; DRUG INDICATION; DRUG SAFETY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; HYPERURICEMIA; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 84864056499     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/edm.12.5     Document Type: Review

References (18)

1. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch. Dermatol. 129(1), 92-96 (1993).
2. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC; SCAR Study Group. Severe Cutaneous Adverse Reactions. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: Results of an international prospective study. Arch. Dermatol. 138(8), 1019-1024 (2002).
3. Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert. Rev. Clin. Immunol. 7(6), 803-815 (2011).
4. Rzany B, Mockenhaupt M, Baur S et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): Structure and results of a population-based registry. J. Clin. Epidemiol. 49(7), 769-773 (1996).
5. Mockenhaupt M. Severe cutaneous adverse reactions. In: BRAUN-Falco's Dermatology (3rd Edition). Burgdorf WHC, Plewig G, Wolff HH, Landthaler M (Eds). Springer Medizin Verlag, Heidelberg, Germany, 473-483 (2008).
6. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 333(24), 1600-1607 (1995).
7. Mockenhaupt M, Viboud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J. Invest. Dermatol. 128(1), 35-44 (2008).
8. Halevy S, Ghislain PD, Mockenhaupt M et al.; EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J. Am. Acad. Dermatol. 58(1), 25-32 (2008).
9. Smith P, Karlson N, Nair BR. Quality use of allopurinol in the elderly. J. Qual. Clin. Pract. 20(1), 42-43 (2000).
10. Devlin JW, Bellamy N, Bayliff CD. Observations and effects of educational consults on allopurinol prescribing. Can. J. Hosp. Pharm. 45(1), 21-27 (1992).
11. Agence Française De Securité Sanitaire des Produits De Santé. Analyse De Ventes De Médicaments aux Officines et aux Hôpitaux en France: 1991-2001 (3ème édition). AFSSAPS, Saint Denis, France (2003).
12. Schwabe U, Paffrath D (Eds.) Arzneimittelverordnungs-Report 2008. Springer Medizin Verlag, Heidelberg , Germany (2008).
13. Khoo BP, Leow YH. A review of inpatients with adverse drug reactions to allopurinol. Singapore Med. J. 41(4), 156-160 (2000).
14. Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102(11), 4134-4139 (2005).
15. Lonjou C, Borot N, Sekula P et al.; RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics 18(2), 99-107 (2008).
16. Pichler WJ, Naisbitt DJ, Park BK. Immune pathomechanism of drug hypersensitivity reactions. J. Allergy Clin. Immunol. 127(Suppl. 3), S74-S81 (2011).
17. Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drughypersensitivity: Pharmacogenetics and clinical syndromes. J. Allergy Clin. Immunol. 127(Suppl. 3), S60-S66 (2011).
18. Dincer HE, Dincer AP, Levinson DJ. Asymptomatic hyperuricemia: To treat or not to treat. Cleve. Clin. J. Med. 69(8), 594, 597, 600-602 (2002).